UY38272A - Inhibidores de proteína tirosina fosfatasa y sus métodos de uso - Google Patents

Inhibidores de proteína tirosina fosfatasa y sus métodos de uso

Info

Publication number
UY38272A
UY38272A UY0001038272A UY38272A UY38272A UY 38272 A UY38272 A UY 38272A UY 0001038272 A UY0001038272 A UY 0001038272A UY 38272 A UY38272 A UY 38272A UY 38272 A UY38272 A UY 38272A
Authority
UY
Uruguay
Prior art keywords
protein tyrosine
tyrosine phosphatase
methods
phosphatase inhibitors
ptpn1
Prior art date
Application number
UY0001038272A
Other languages
English (en)
Inventor
Elliot Farney
Roohollah Kazem Shiroodi
Zhaoming Xiong
Qingwei I Zhang
Matthew O’Connor
Geoff Halvorsen
Hongyu Zhao
Christina Baumgartner
Jennifer M Frost
Phil Kym
Jason R Abbott
Andrew Bogdan
Christos Economou
Xueqing Wang
Original Assignee
Abbvie Inc
Calico Life Sciences Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Inc, Calico Life Sciences Llc filed Critical Abbvie Inc
Publication of UY38272A publication Critical patent/UY38272A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/10—1,2,5-Thiadiazoles; Hydrogenated 1,2,5-thiadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
    • C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • C07D285/13—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Abstract

Se proporcionan en la presente compuestos, composiciones y métodos útiles para inhibir proteína tirosina fosfatasa, por ejemplo, proteína tirosina fosfatasa no receptora de tipo 2 (PTPN2) y/o proteína tirosina fosfatasa no receptora de tipo 1 (PTPN1) y para tratar enfermedades, trastornos y condiciones relacionadas que responden favorablemente al tratamiento con inhibidor de PTPN1 o PTPN2, por ejemplo, un cáncer o una enfermedad metabólica.
UY0001038272A 2018-06-21 2019-06-21 Inhibidores de proteína tirosina fosfatasa y sus métodos de uso UY38272A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862688226P 2018-06-21 2018-06-21

Publications (1)

Publication Number Publication Date
UY38272A true UY38272A (es) 2019-12-31

Family

ID=67254011

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001038272A UY38272A (es) 2018-06-21 2019-06-21 Inhibidores de proteína tirosina fosfatasa y sus métodos de uso

Country Status (23)

Country Link
US (1) US10954202B2 (es)
EP (1) EP3810580A1 (es)
JP (2) JP7217762B2 (es)
KR (2) KR102533477B1 (es)
CN (1) CN112955438A (es)
AR (1) AR125425A1 (es)
AU (2) AU2019290197B2 (es)
BR (1) BR112020026086A2 (es)
CA (1) CA3104507A1 (es)
CL (1) CL2020003316A1 (es)
CO (1) CO2021000447A2 (es)
CR (1) CR20210017A (es)
DO (1) DOP2020000252A (es)
EC (1) ECSP21003520A (es)
IL (1) IL279587A (es)
MA (1) MA52963A (es)
MX (1) MX2020014223A (es)
PE (1) PE20210372A1 (es)
PH (1) PH12020552228A1 (es)
SG (1) SG11202012820PA (es)
TW (1) TW202016082A (es)
UY (1) UY38272A (es)
WO (1) WO2019246513A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3765094A4 (en) 2018-03-15 2021-12-22 KSQ Therapeutics, Inc. GENE REGULATION COMPOSITIONS AND METHODS FOR IMPROVING IMMUNOTHERAPY
CA3131894A1 (en) * 2019-03-14 2020-09-17 Calico Life Sciences Llc Protein tyrosine phosphatase inhibitors and methods of use thereof
AU2020395612A1 (en) * 2019-12-04 2022-06-09 Monash University Methods of activating cytotoxic leukocytes using PTP1B and PTPN2 inhibitors
MX2022007441A (es) * 2019-12-18 2022-09-02 Calico Life Sciences Llc Inhibidores de proteína tirosina fosfatasa y sus métodos de uso.
CA3223322A1 (en) * 2021-06-21 2022-12-29 Gesine Kerstin Veits Degrader compounds and uses thereof
WO2023086495A1 (en) * 2021-11-11 2023-05-19 Calico Life Sciences Llc Protein tyrosine phosphatase inhibitors and methods of use thereof
CA3236854A1 (en) * 2021-11-11 2023-05-19 Andrew Bogdan Protein tyrosine phosphatase inhibitors and methods of use thereof
CN116675653A (zh) * 2022-07-22 2023-09-01 中国药科大学 氨基烷基取代的1,2,4-噻二唑烷-3,5-二酮化合物及其制备方法和应用
WO2024059041A1 (en) * 2022-09-13 2024-03-21 Kumquat Biosciences, Inc. Benzo-fused n-heterocycles and uses thereof
CN117343052B (zh) * 2023-12-04 2024-02-06 英矽智能科技(上海)有限公司 蛋白酪氨酸磷酸酶抑制剂及其应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4911920A (en) 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
FR2588189B1 (fr) 1985-10-03 1988-12-02 Merck Sharp & Dohme Composition pharmaceutique de type a transition de phase liquide-gel
ATE141502T1 (de) 1991-01-15 1996-09-15 Alcon Lab Inc Verwendung von karrageenan in topischen ophthalmologischen zusammensetzungen
US5212162A (en) 1991-03-27 1993-05-18 Alcon Laboratories, Inc. Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
JP4846978B2 (ja) 2001-10-30 2011-12-28 メルク セローノ ソシエテ アノニム タンパク質チロシンホスファターゼのオキシンドールヒドラジンモジュレータ
CN1646508A (zh) * 2002-04-03 2005-07-27 诺瓦提斯公司 作为ptp酶1b抑制剂的5－取代的1,1－二氧代－1,2,5－噻二唑烷－3－酮衍生物
GB0225986D0 (en) * 2002-11-07 2002-12-11 Astrazeneca Ab Chemical compounds
UA94921C2 (en) * 2005-12-08 2011-06-25 Новартис Аг 1-orthofluorophenyl substituted 1, 2, 5-thiazolidinedione derivatives as ptp-as inhibitors
WO2008142198A2 (en) 2007-05-23 2008-11-27 Valtion Teknillinen Tutkimuskeskus A method for inhibiting or stimulating angiogenesis in an individual
WO2010008852A2 (en) 2008-06-23 2010-01-21 Taiga Biotechnologies, Inc. Methods of trea fing λλd methods of diagnosing an immunoproliferative disorder
WO2010118241A2 (en) 2009-04-08 2010-10-14 Indiana University Research & Technology Corporation Inhibitors of protein tyrosine phosphatases
WO2011057331A1 (en) 2009-11-11 2011-05-19 Monash University A method for treating obesity
EP2531616A4 (en) 2010-02-03 2013-07-10 Univ Monash DIAGNOSTIC AND PROGNOSIS ASSAY FOR BREAST CANCER
WO2015127548A1 (en) 2014-02-28 2015-09-03 The Royal Institution For The Advancement Of Learning / Mcgill University Tc-ptp inhibitors as apc activators for immunotherapy
WO2015188228A1 (en) 2014-06-10 2015-12-17 Monash University Method of producing leukocytes using ptpn2 inhibition for adoptive cell transfer
KR101826690B1 (ko) 2015-11-06 2018-03-22 경북대학교 산학협력단 단백질 타이로신 탈인산화효소 억제제를 포함하는 신경염증성 질환의 예방 또는 치료용 조성물
WO2017078499A2 (ko) 2015-11-06 2017-05-11 경북대학교 산학협력단 단백질 타이로신 탈인산화효소 억제제를 포함하는 신경염증성 질환의 예방 또는 치료용 조성물
WO2018148378A1 (en) 2017-02-08 2018-08-16 Dana-Farber Cancer Institute, Inc. Modulating biomarkers to increase tumor immunity and improve the efficiacy of cancer immunotherapy
US11273166B2 (en) 2017-06-13 2022-03-15 Monash University Methods and compositions for the treatment of obesity
WO2019036815A1 (en) 2017-08-24 2019-02-28 The Royal Institution For The Advancement Of Learning/Mcgill University ENHANCEMENT OF CD8 + T LYMPHOCYTES FOR ADOPTIVE CELL THERAPY BY INHIBITING PTPN1 (PTP1B) AND PTPN2 (TC-PTP))

Also Published As

Publication number Publication date
KR20210034589A (ko) 2021-03-30
CN112955438A (zh) 2021-06-11
JP7217762B2 (ja) 2023-02-03
PH12020552228A1 (en) 2021-08-16
US10954202B2 (en) 2021-03-23
MA52963A (fr) 2021-04-28
CR20210017A (es) 2021-11-03
CA3104507A1 (en) 2019-12-26
KR20230074286A (ko) 2023-05-26
TW202016082A (zh) 2020-05-01
PE20210372A1 (es) 2021-02-26
AR125425A1 (es) 2023-07-19
WO2019246513A1 (en) 2019-12-26
JP2021530443A (ja) 2021-11-11
IL279587A (en) 2021-03-01
US20210009542A1 (en) 2021-01-14
CL2020003316A1 (es) 2021-06-11
DOP2020000252A (es) 2021-07-15
AU2023263567A1 (en) 2023-11-30
SG11202012820PA (en) 2021-01-28
JP2023055771A (ja) 2023-04-18
EP3810580A1 (en) 2021-04-28
AU2019290197B2 (en) 2023-08-24
BR112020026086A2 (pt) 2021-03-23
ECSP21003520A (es) 2021-02-26
MX2020014223A (es) 2021-06-23
KR102533477B1 (ko) 2023-05-18
CO2021000447A2 (es) 2021-07-19
AU2019290197A1 (en) 2021-01-21

Similar Documents

Publication Publication Date Title
CO2021000447A2 (es) Inhibidores de proteína tirosina fosfatasa y sus métodos de uso
UY38613A (es) Inhibidores de la proteína tirosina fosfatasa y mètodos de uso de los mismos
UY38999A (es) Degradadores de proteína tirosina fosfatasa y métodos de uso de los mismos
CL2019001711A1 (es) Composiciones y métodos para inhibir la acción de la arginasa.
CL2020002146A1 (es) Derivados de n-(fenil)-2-(fenil)pirimidina-4-carboxamida y compuestos relacionados como inhibidores hpki para tratar el cáncer.
CL2017002494A1 (es) Inhibidores de indolamina-2, 3- dioxigenasa para el tratamiento de cancer
MX2020004534A (es) Moduladores de la vía integrada del estrés.
EA201691135A1 (ru) Новые ингибиторы глутаминазы
CO2021001472A2 (es) Inhibidores de transglutaminasa 2 (tg2)
CO2021004141A2 (es) Moduladores de la expresión de pnpla3
MX2017015923A (es) Inhibidores de indolamina-2,3-dioxigenasa (ido).
MX2022007441A (es) Inhibidores de proteína tirosina fosfatasa y sus métodos de uso.
CO2023010023A2 (es) Inhibidores de cdk2 y métodos de uso de los mismos
NI202000085A (es) Moduladores de la expresión de apol1
BR112019002458A2 (pt) composições e métodos para tratar câncer com depleção de arginina e agentes imuno-oncológicos
CO2021007006A2 (es) Moduladores de la expresión de irf5
BR112022005895A2 (pt) Inibidores de aldose redutase para tratamento de deficiência de fosfomanomutase 2
CL2021003442A1 (es) Composición farmacéutica que comprende idelalisib y defactinib; y métodos para el tratamiento de cáncer.
BR112022010672A2 (pt) Agentes ativos acilados e métodos de seu uso para o tratamento de distúrbios metabólicos e doença hepática gordurosa não alcoólica
ECSP21042779A (es) Moduladores de la expresión de irf5
EA201991267A1 (ru) Ингибиторы мутантных изоцитратдегидрогеназ и их композиции и способы